Q4 2025 Verastem Inc Earnings Call Transcript

Mar 4, 2026 / 09:30 PM GMT

Release Date Price: €4.96 (+2.06%)

Transcript 10-K

Key Points

Positve

Verastem Inc (VSTM) transitioned to a commercial stage company with FDA approval for the first treatment specifically for KRAS mutated recurrent low-grade serous ovarian cancer.
The company reported $30.9 million in net product revenue for the launch period of May through December 2025, with $17.5 million in the fourth quarter alone.
Steady growth in product adoption was observed among both academic centers and community oncologists.
The combination of ivutametinib plus defactinib has shown promising anti-tumor activity in pancreatic cancer, a highly KRAS-driven cancer.
Verastem Inc (VSTM) has extended its cash runway into the first half of 2027, providing financial stability to advance near-term milestones.

Negative

The updated NCCN ovarian cancer guidelines did not expand the recommendation for rutametinib plus defactinib to include patients without a KRAS mutation, which was disappointing for the company.
The company faces challenges in securing reimbursement for KRAS wild-type patients, although they have been successful so far.
Research and development expenses were high, totaling $114.6 million for the full year 2025.
The company reported a non-GAAP adjusted net loss of $163.1 million for 2025, indicating financial challenges.
There is a need for continued prioritization of opportunities due to limited resources, which may impact the pace of development and commercialization efforts.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VSTM.OQ - Verastem Inc
Q4 2025 Verastem Inc Earnings Call
Mar 04, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Verastem Oncology's 4th quarter and full year 2025 earnings conference call. My name is Desiree, and I will be your call operator today. Please note this event is being recorded. All participants will be in a listen-only mode.

After today's presentation, there will be an opportunity to ask questions.

I will now turn the call over to Julissa Vienna, Vice President of Corporate Communications, Investor relations and patient advocacy at Veristem Oncology.

Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.